Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Comparing EvoLV to McKinsey: Choosing the Right Biotech Advisory Partner

Jun 22, 2026By Sreejith Kanhirangadan

SK

Understanding the Role of Biotech Advisory Partners

When navigating the complex biotech landscape, selecting the right advisory partner can significantly impact your business's success. Two prominent names in this sector are EvoLV and McKinsey. Both offer valuable expertise but cater to different niches within the biotech industry. Understanding their strengths and focus areas can help you make an informed decision.

Biotech firms often face unique challenges that require specialized knowledge and strategic insight. Whether it's navigating regulatory hurdles, optimizing R&D processes, or scaling operations, the right advisory partner can provide a roadmap to success. EvoLV and McKinsey both offer distinct advantages, and your choice should align with your company's specific needs and goals.

biotech consulting

What EvoLV Brings to the Table

EvoLV is renowned for its deep focus on the biotech industry. This specialization allows EvoLV to provide targeted solutions that address the nuanced challenges biotech companies face. Their team consists of industry veterans with a wealth of experience in biotech-specific issues, from drug development to commercialization strategies.

One of EvoLV's standout features is its emphasis on innovation. They are adept at identifying emerging trends and technologies, helping clients stay ahead of the curve. If your company values cutting-edge solutions and a partner who understands the intricacies of biotech, EvoLV might be the right fit.

biotech innovation

The McKinsey Advantage

On the other hand, McKinsey is a giant in the consulting world, offering a broad range of services across multiple industries, including biotech. Their strength lies in their vast resources and global reach. With a large network of experts, McKinsey can provide insights that span different sectors, which can be beneficial for biotech companies looking to expand or diversify.

McKinsey is known for its strategic approach to problem-solving. They focus on data-driven insights and have a track record of delivering measurable results. If your biotech firm seeks a comprehensive strategy that leverages cross-industry expertise, McKinsey could be a valuable partner.

global consulting

Key Factors to Consider

When deciding between EvoLV and McKinsey, consider the following factors:

  • Industry Focus: EvoLV’s biotech specialization vs. McKinsey’s cross-industry approach.
  • Innovation vs. Strategy: EvoLV’s focus on innovation compared to McKinsey’s strategic methodologies.
  • Resource Availability: The personalized service of EvoLV versus the extensive resources of McKinsey.

Assess your company's current needs and future goals to determine which partner’s strengths align best with your objectives.

Conclusion

Both EvoLV and McKinsey offer invaluable expertise in the biotech sector, but their distinct approaches cater to different organizational needs. Whether you prioritize specialized innovation or strategic breadth, choosing the right advisory partner can propel your biotech company towards substantial growth and success.

Ultimately, the decision should reflect your company’s unique challenges and aspirations. By understanding the strengths of each firm, you can select a partner that will guide your business effectively through the ever-evolving biotech landscape.